ProJenX has received USD 1 million in funding through the Hoffman Amyotrophic Lateral Sclerosis (ALS) Clinical Trials Award delivered by the ALS Association. The funding was granted to recognize the therapeutic potential of prosetin, ProJenX's ALS candidate.
The obtained funds will be directed toward the development of ProJenX's candidate, prosetin, in the Part 1c portion of the PRO-101 clinical trial. Patient enrollment for the trial is expected to start in Q3 2024. The trial is aimed at evaluating the safety, tolerability, pharmacokinetics, and pharmacodynamics of protein for the treatment of ALS.
By using this site, you agree to allow SPEEDA Edge and our partners to use cookies for analytics and personalization. Visit our privacy policy for more information about our data collection practices.